Main Article Content
Herd immunity or herd effect is a phenomenon that occurs in groups of people who are resistant to disease. The purpose of conducting this research is to predict the number of cumulative cases of COVID-19 in Indonesia. Covid-19 cases in Indonesia on April 6, 2020, were 2235 cases spread in 34 Provinces. As many as 2491 cases in Indonesia, there were 192 patients recovered (including those treated, so they have natural antibodies in the end) while the total who died was 209 people. It is assumed that around 13% of the total cases have natural antibodies. This is also the case with SARS-CoV-2 and may explain why some individuals (perhaps those most recently able to recover from seasonal coronavirus infections) have asymptomatic infections. Finally, the theoretical concept of increasing herd immunity in pandemic and epidemic cases in Indonesia which aims to control COVID-19 still needs to be reviewed because it is seen from the mortality data that CFR COVID-19 is predicted to be around 8.39% of the population in Indonesia where the risk of death still available. The best alternative is to do a healthy lifestyle, social distancing, and waiting for the vaccine to be found.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.
JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
- BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
2. John, T.J & Samuel, R. Herd immunity and herd effect: new insights and definitions. European Journal of Epidemiology 2000, 16: 601-6. www.jstor.org/stable/3582376.
3. Fine, P., Earnes, K., & Heymann, D.L. "Herd Immunity" : A Rough Guide. CID 2011, 52: 911-15. doi.org/10.1093/cid/cir007.
4. Murphy K, Weave C. Janewayâ€™s Immunobiology. 9th ed. (Divakaran D, ed.). New York: Garland Science, Taylor & Francis Group, LLC; 2017.
5. Smith, D.R. Herd Immunity. Vet Clin Food Anim 2019; 35: 593-9. doi.org/10.1016/j.cvfa.2019.07.001.
6. Betsh, C., Bohm, R., Korn, L., & Holtmann, C. On the benefits of explaining herd immunity in vaccine advocacy. Nature human behaviour 2017, 1 (0056) : 1-6. doi.org/10.1038/s41562-017-0056.
7. Smith, P.G. Concepts of herd protection and immunity. Procedia in Vaccinology 2010, 2 : 134-9. doi.org/10.1016/j.provac.2010.07.005.
8. Randolph, H.E., & Barreiro, L.B. Herd Immunity : Understanding COVID-19. Immunity 2020, 52: 737 â€“ 41. doi.org/10.1016/j.immuni.2020.04.012.
9. Belouzard, S., Miller, J.K., Licitra, B.N., & Whittaker, G.R. Mechanisms of Coronavirus Cell entry Mediated by Viral Spike Protein. Viruses 2012, 4: 1011-33. doi.org/10.3390/v4061011.
10. Li, X., Geng, M., Peng, Y., Meng, L., and Lu, S. Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis 2020, XXX (XXXX): 1-7.
11. eCDC. European Centre for Disease : COVID-19. Accesed April 18, 2020 from www.ecdc.europa.eu/en/coronavirus.
12. Raoult, D., Zumla, A., Locatelli, F., Ippolito, G., and Kroemer, G. Coronavirus infections :epidemiological, clinical and immunological features and hypotheses. Cell press 2020, 1-6. doi.org/10.15698/cst2020.04.216.
13. Singh, B.R. R0 value & Herd immunity (Herd Effect/Community Immunity/Population Immunity/Social Immunity. 2020. India : Indian Veterinary Reseacrh Institute. Pp: 10-www.slideshare.net/singh_br1762/r0-value-herd-immunity.
14. Kumar, V. Herd Immunity. 2020. India : Indian Veterinary Reseacrh Institute. Pp: 10-9. www.slideshare.net/vetvinodh/herd-immunity-48091837.
15. Mallory, M. L., Lindesmith, L. C., & Baric, R. S. Vaccination-Induced herd Immunity : Successes and Challenge. J Allergy Clin Immunol 2018, 142(1) : 64â€“6. doi.org/10.1016/j.jaci.2018.05.007.
16. Kim, T. A. E. H., Johnstone, J., & Loeb, M. Vaccine herd effect, Scandinavian Journal of Infectious Disease 2011, 43: 683â€“9. doi.org/10.3109/00365548.2011.582247.
17. Metcalf, C. J. E., Ferrari, M., & Grenfell, B. T. Understanding Herd Immunity. Trends in Immunology 2015, 36(12) : 753â€“5. dx.doi.org/10.1016/j.it.2015.10.004.
18. Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv 2020, 1-20. doi.org/10.1101/2020.03.30.20047365.
19. Kwok, K. O., Lai, F., Wei, W. I., Yeung, S., Wong, S., & Tang, J. Herd Immunity â€“ Estimating The Level Required To Halt The COVID-19 Epidemics In Affected Countries. Journal of Infection 2020, 80 (6), e32-3. doi.org/10.1016/j.jinf.2020.03.027.
20. Adnan, M., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. COVID-19 infectionâ€¯: Origin , transmission , and characteristics of human coronaviruses. Journal of Advanced Research 2020, 24: 91â€“98. doi.org/10.1016/j.jare.2020.03.005.
21. Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N. Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., Dighe, A., Griffin, J. T., Baguelin, M., Bhatia, S., Boonyasiri, A., Cori, A., CucunubÃ¡, Z., FitzJohn, R., Gaythorpe, K., & Ferguson, N. M. Articles Estimates of the severity of coronavirus disease 2019â€¯: a model-based analysis. Lancet Infect Disc 2020, 3099(20), 1â€“9. doi.org/10.1016/S1473-3099(20)30243-7.
22. Lai, C., Liu, Y. H., Wang, C., Wang, Y., Hsueh, S., Yen, M., Ko,W.C., & Hsueh, P. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARSCoV-2): Facts and myths. Journal of Microbiology, Immunology and Infection 2020, 2 : 1-10. doi.org/10.1016/j.jmii.2020.02.012.
23. Sen-crowe, B., Mckenney, M., & Elkbuli, A. Social Distancing During The Covid-19 Pendemic: Staying Home Save Lives. American Journal of Emergency Medicine 2020, doi.org/10.1016/j.ajem.2020.03.063.
24. Aminjafari, A., & Ghasemi, S. The possible of immunotherapy for COVID-19: A systemic review. International Immunopharmacology 2020, 83 : 106455. doi.org/10.1016/j.intimp.2020.106455.